Fragmented Tissue Factor Pathway Inhibitor (TFPI) and TFPI C‐Terminal Peptides Eliminate Serum‐ResistantEscherichia colifrom Blood Cultures | Zendy

Sabine Schirm | Zendy; Xu Liu | Zendy; Lori L. Jennings | Zendy; Paul T. Jedrzejewski | Zendy; Yumin Dai | Zendy; Stephen Hardy | Zendy

Open Access

Fragmented Tissue Factor Pathway Inhibitor (TFPI) and TFPI C‐Terminal Peptides Eliminate Serum‐ResistantEscherichia colifrom Blood Cultures

Author(s) -

Sabine Schirm,

Xu Liu,

Lori L. Jennings,

Paul T. Jedrzejewski,

Yumin Dai,

Stephen Hardy

Publication year - 2009

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/599097

Subject(s) - tissue factor pathway inhibitor , complement system , microbiology and biotechnology , escherichia coli , ex vivo , biology , sepsis , innate immune system , tissue factor , coagulation , alternative complement pathway , immunology , immune system , medicine , biochemistry , in vitro , psychiatry , gene

Tissue factor pathway inhibitor (TFPI) is a major regulator of blood clotting. Receipt of recombinant TFPI (rTFPI) protected animals from death in Escherichia coli-induced severe sepsis models and is under evaluation in a phase III clinical trial involving patients with severe community-acquired pneumonia. Because the mechanism of action of rTFPI in acute bacterial infection is not well understood, we sought to identify and map rTFPI peptides that have antimicrobial activity against E. coli.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research